Connect Biopharma to Participate at the SVB Leerink 11th Annual Global Healthcare Conference
February 09 2022 - 7:00AM
Connect Biopharma Holdings Limited (Nasdaq: CNTB) ("Connect
Biopharma" or the “Company”), a global clinical-stage
biopharmaceutical company dedicated to improving the lives of
patients with chronic inflammatory diseases through the development
of therapies derived from T cell-driven research, today announced
that Dr. Zheng Wei, Co-Founder & CEO, will participate in a
fireside chat at the SVB Leerink 11th Annual Global Healthcare
Conference on Wednesday, February 16, 2022 at 4:20 pm ET.
A webcast of this fireside chat will be
available on the Company’s Investor Relations page accessible here:
https://investors.connectbiopharm.com/. A replay will be available
on the Company’s website following the event.
About Connect Biopharma Holdings
LimitedConnect Biopharma Holdings Limited is a global
clinical-stage biopharmaceutical company dedicated to improving the
lives of patients living with chronic inflammatory diseases through
the development of therapies derived from our T cell-driven
research.
Our lead product candidate, CBP-201 — an
antibody designed to target interleukin-4 receptor alpha (IL-4Rα) —
has been in clinical trials for the treatment of AD, asthma, and
CRSwNP. Our second lead product candidate, CBP-307 — a modulator of
a T cell receptor known as sphingosine 1-phosphate receptor 1
(S1P1) — has been in clinical trials for the treatment of
ulcerative colitis (UC) and Crohn’s disease (CD). Furthermore, we
have started the clinical development of an additional product
candidate, CBP-174 — a peripherally acting antagonist of histamine
receptor 3 — for the treatment of pruritus associated with AD.
With clinical development activities in the
United States, China, Europe, and Australia, and operations in
those geographies as well as Hong Kong, Connect Biopharma is
building a rich global pipeline of internally designed, wholly
owned small molecules and antibodies targeting several aspects of T
cell biology. For additional information about Connect Biopharma,
please visit our website at www.connectbiopharm.com.
IR/PR Contacts: Lazar FINN
Partners David Carey (IR) T: +1-(212)
867-1768david.carey@finnpartners.comErich Sandoval (Media)T:
+1-(917)-497-2867erich.sandoval@finnpartners.comCorporate
Contacts:info@connectpharm.com
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Connect Biopharma (NASDAQ:CNTB)
Historical Stock Chart
From Sep 2023 to Sep 2024